ArticleThe oncologist2026
Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized. MATERIAL AND
methodsWe conducted a retrospective cohort study of patients with LA/mUC treated with EVP at MD Anderson Cancer Center. Pneumonitis was adjudicated by pulmonology and graded using CTCAE v5.0. Prior immune checkpoint inhibitor (ICI) exposure was defined as ICI treatment before EVP initiation. Risk factors were assessed using Cox proportional hazards and Fine-Gray competing-risk regression; associations with overall survival (OS) and progression-free survival (PFS) were evaluated using extended Cox models.
resultsPneumonitis occurred in 22 patients (7.0%), with median onset at 77 days; 10 events (45%) were grade ≥3, including 1 fatal case. Prior ICI exposure was the strongest independent predictor of pneumonitis (any-grade adjusted HR 2.68; 95% CI, 1.03-6.98; P = .04; grade ≥2 adjusted HR 5.91; 95% CI, 1.94-18.02; P = .002). No other baseline variable was significantly associated with pneumonitis. Grade ≥2 pneumonitis was associated with increased mortality (HR 2.35; 95% CI, 1.02-5.45; P = .04), whereas any-grade pneumonitis was not. Twelve patients underwent treatment re-exposure; all had no clinically meaningful recurrent or worsening pneumonitis during subsequent evaluable follow-up, with 8 resuming EV plus pembrolizumab and 4 EV alone.
conclusionPneumonitis occurred in 7.0% of EVP-treated patients and generally arose early. Prior ICI exposure predicted pneumonitis, particularly grade ≥2 events, which were associated with increased mortality; any-grade pneumonitis and PFS were not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.